NEW YORK — At OSN New York 2015, Carlos Buznego, MD, talks about growing patient demand in femtosecond cataract surgery.
Uncategorized
Uncategorized
RXi initiates phase 1/2 clinical trial of RXI-109 for retinal scarring
RXi Pharmaceuticals has initiated RXI-109-1501, a phase 1/2 clinical trial evaluating the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, according to a press release. RXI-109-1501 includes patients diagnosed wit…
MedPAC Explores New Primary Care Bonus
(MedPage Today) — Panel mulls ideas for keeping primary care financially attractive
Ocata Therapeutics to Host Conference Call and Webcast to Provide Corporate Update for the Third Quarter of 2015
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™ announced today that it will host a conference call on Monday, November 9th, 2015 at 8:30 a.m. EST, during which it will provide a corporate update for the third quarter of 2015. Interested parties may access the call live by dialing (888) 539-3679 (US) or (719) 325-2370 (international) and using conference ID 1107447. A live audio webcast of the presentation will b
Uncategorized
Allergan reports Q3 results, including 90% increase in net revenue
Allergan reported net revenue increasing 90% to $4.1 billion for the quarter ending Sept. 30, compared with $2.2 billion in the third quarter of 2014, according to a press release.“These strong results were driven by our continued focus on customers, fueling volume driven year-over-year growth in our U.S. Brands, Medical Aesthetics, International Brands and Anda Distribution segments, while also executing preintegration activities ahead of the divestiture of the Generics business to Teva, which remains on track to be completed by the first quarter of 2016,” Brent Saunders, CEO and president (Read more...)
Uncategorized
Aerie reports $18 million GAAP net loss
Aerie Pharmaceuticals reported a GAAP net loss of $18 million, or $0.69 per share, in the third quarter compared with a GAAP net loss of $13.1 million, or $0.54 per share, in the same quarter of 2014, according to a press release. Operating expenses we…